Dr. Antonio Risitano, University of Naples and Dr. Regis Peffault DeLatour, Hospital de St. Louis, discuss recent research on treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
Dr. Timothy Graubert, Massachusetts General Hospital and Dr. Stephanie Halene, Yale University School of Medicine discuss the highlights of their session on the Biology of Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
Here is what one expert says about the right time to start treating relapsed multiple myeloma.
We spoke to ovarian cancer survivors about their advice for women who are newly diagnosed.
High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.
Should cancers that are not traditionally associated with Lynch syndrome or MSI-H status be tested? This expert thinks so.
Audra Moran, president and CEO of the Ovarian Cancer Research Fund Alliance, discusses the support available for caregivers of women with ovarian cancer.
Saketh Guntupalli, M.D., gynecologic oncologist at the University of Colorado Hospital, discusses ways that women can improve intimacy after an ovarian cancer diagnosis.
There are many exciting advances happening in the field of mantle cell lymphoma.
Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.
Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.
We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.
Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.
Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.
An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).
There are some key discussions that men with metastatic prostate cancer should have with their health care providers.
Researchers should not give up hope in using immunotherapy to treat brain cancers.
As the number of patients and survivors continues to increase, it is important that clinician burnout is handled appropriately, explains Thomas A. Gallo.
It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.
Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.
By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.
As cancer survivors are living longer thanks to new treatments, it is essential that health care providers and researchers put more focus on depression.
Over the past few decades, prostate cancer has become better understood and treated more effectively.
The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.
A lack of vitamin D can have major impacts on myeloma treatment outomes.
The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.
The Leukemia & Lymphoma Society's (LLS) Clinical Trial Support Center helps patients with blood cancers find clinical trials that are right for them.
After finding out she had an MPN, Barbara Abernathy, Ph.D., like many other people, felt numb. But then it was time to find her fight mode.
Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.
